CASI Pharmaceuticals Inc (CASI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CASI Pharmaceuticals Inc (CASI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10007
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the acquisition, development and commercialization of innovative therapies for treating cancer and other unmet medical needs. Its pipeline product portfolio includes ENMD-2076 that is being developed globally for the treatment of various cancers including triple-negative breast cancer, soft-tissue sarcoma, ovarian clear cell carcinoma and fibrolamellar carcinoma. The company’s pipeline also includes three in-licensed oncology products, namely, Zevalin for non-Hodgkin’s lymphoma; Marqibo for acute lymphoblastic leukemia; and Evomela (melphalan) for multiple myeloma. The company operates subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.

CASI Pharmaceuticals Inc (CASI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
CASI Pharma Acquires HBV ANDA from Laurus Labs 11
CASI Pharma Acquires ANDA Portfolio from Sandoz 12
Licensing Agreements 13
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 13
Equity Offering 15
CASI Pharma to Raise USD48.5 Million in Private Placement of Shares 15
CASI Pharma to Raise USD50 Million in Private Placement of Shares 16
CASI Pharma to Raise up to USD25 Million in Public Offering of Shares 17
CASI Pharma to Raise USD23.8 Million in Private Placement of Units 18
CASI Pharma Raises USD3 Million in Private Placement of Shares 19
CASI Pharma Raises USD7.8 Million in Final Tranche of Private Placement of Shares 20
CASI Pharma Raises USD1 Million in Third Tranche of Private Placement of Shares 21
CASI Pharma Raises USD6 Million in Second Tranche of Private Placement of Shares 22
CASI Pharma Raises USD10.3 Million in First Tranche of Private Placement of Shares and Warrants 23
Entremed Completes Private Placement Of Units For US$11 Million 24
Debt Offering 25
EntreMed Completes Private Placement Of Convertible Notes Due 2012 For US$10 Million 25
CASI Pharmaceuticals Inc – Key Competitors 27
CASI Pharmaceuticals Inc – Key Employees 28
CASI Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 14, 2018: CASI Pharmaceuticals announces second quarter and first half 2018 financial and business results 30
May 15, 2018: CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results 32
Mar 29, 2018: CASI Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results 34
Nov 14, 2017: CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results 36
Aug 14, 2017: CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results 37
May 15, 2017: CASI Pharmaceuticals Reports First Quarter 2017 Financial Results 38
Mar 31, 2017: CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results 39
Corporate Communications 40
Oct 02, 2018: CASI Pharmaceuticals appoints Larry Zhang as president to its China operations to lead commercialization 40
Jul 03, 2018: CASI Pharmaceuticals Added To Russell 2000, 3000 And Microcap Indexes 41
Product News 42
03/28/2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting 42
Clinical Trials 43
Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC) 43
Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076 44
May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma 45
May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer 46
Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CASI Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CASI Pharma Acquires HBV ANDA from Laurus Labs 11
CASI Pharma Acquires ANDA Portfolio from Sandoz 12
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 13
CASI Pharma to Raise USD48.5 Million in Private Placement of Shares 15
CASI Pharma to Raise USD50 Million in Private Placement of Shares 16
CASI Pharma to Raise up to USD25 Million in Public Offering of Shares 17
CASI Pharma to Raise USD23.8 Million in Private Placement of Units 18
CASI Pharma Raises USD3 Million in Private Placement of Shares 19
CASI Pharma Raises USD7.8 Million in Final Tranche of Private Placement of Shares 20
CASI Pharma Raises USD1 Million in Third Tranche of Private Placement of Shares 21
CASI Pharma Raises USD6 Million in Second Tranche of Private Placement of Shares 22
CASI Pharma Raises USD10.3 Million in First Tranche of Private Placement of Shares and Warrants 23
Entremed Completes Private Placement Of Units For US$11 Million 24
EntreMed Completes Private Placement Of Convertible Notes Due 2012 For US$10 Million 25
CASI Pharmaceuticals Inc, Key Competitors 27
CASI Pharmaceuticals Inc, Key Employees 28
CASI Pharmaceuticals Inc, Other Locations 29
CASI Pharmaceuticals Inc, Subsidiaries 29

List of Figures
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[CASI Pharmaceuticals Inc (CASI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Teekay Offshore Partners L.P.:企業のM&A・事業提携・投資動向
    Teekay Offshore Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Teekay Offshore Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Baylor College of Medicine:企業のM&A・事業提携・投資動向
    Baylor College of Medicine - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Baylor College of Medicine Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Astron Corp Ltd (ATR):企業の財務・戦略的SWOT分析
    Astron Corp Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • iBio Inc (IBIO):企業の財務・戦略的SWOT分析
    Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclo …
  • QT Vascular Ltd (5I0):医療機器:M&Aディール及び事業提携情報
    Summary QT Vascular Ltd (QT Vascular) is a medical device manufacturing company that offers developing, manufacturing and distributing of advanced therapeutic solutions for the treatment of complex vascular diseases. The company’s products include coronary products such as Chocolate PTCA Balloon Cat …
  • CIMB Group Holdings Berhad:企業のM&A・事業提携・投資動向
    CIMB Group Holdings Berhad - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CIMB Group Holdings Berhad Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Martin Midstream Partners LP (MMLP):石油・ガス:M&Aディール及び事業提携情報
    Summary Martin Midstream Partners LP (Martin Midstream) is a midstream service provider that carries out the transportation, storage and distribution of petroleum products and by-products. Its service offerings include terminalling, transportation, distribution, and midstream logistical services, be …
  • EyePoint Pharmaceuticals Inc (PSDV):企業の財務・戦略的SWOT分析
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. EyePoint dura …
  • Teco Energy Inc:電力:M&Aディール及び事業提携情報
    Summary TECO Energy Inc (TECO), a subsidiary of Emera Inc., is an energy holding company for regulated electricity and gas utilities and other businesses. It generates, transmits, distributes, purchases and sells electricity; and purchases, distributes and sells natural gas through its subsidiaries. …
  • Lufthansa Cityline Gmbh:企業の戦略・SWOT・財務情報
    Lufthansa Cityline Gmbh - Strategy, SWOT and Corporate Finance Report Summary Lufthansa Cityline Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • PharmaCyte Biotech Inc (PMCB)-医療機器分野:企業M&A・提携分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company’s technology is used for the treatment of advanced and inoperable pancreatic cancer, and diabetes. It develops …
  • Malaysian Resources Corporation Berhad (MRCB):企業の財務・戦略的SWOT分析
    Malaysian Resources Corporation Berhad (MRCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Vodafone Group Plc (VOD):企業の財務・戦略的SWOT分析
    Vodafone Group Plc (VOD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • FLSmidth & Co. A/S:企業の戦略・SWOT・財務情報
    FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report Summary FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Episurf Medical AB (EPIS B):企業の財務・戦略的SWOT分析
    Summary Episurf Medical AB (Episurf Medical), formerly Diamorph Medtech AB is a medical technology company that provides patient-specific treatments of painful joint injuries. It offers diagnosis and design of implants and surgical instruments. Its products include Episealer Femoral Twin, Episealer …
  • HealthTronics Inc:企業の戦略的SWOT分析
    HealthTronics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Permasteelisa S.p.A.:企業の戦略・SWOT・財務情報
    Permasteelisa S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Permasteelisa S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Omega Diagnostics Group Plc (ODX):企業の財務・戦略的SWOT分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company provides products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests …
  • Fresenius SE & Co KGaA (FRE)-製薬・医療分野:企業M&A・提携分析
    Summary Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes mach …
  • New Image Group Ltd:企業の戦略的SWOT分析
    New Image Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆